Physician profile
Ann M Lee
NPI 1619960556
$8,759.74
in general payments reported to CMS, 2019-2025
45 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,677 · 2020: $732 · 2021: $825 · 2022: $1,567 · 2023: $563 · 2024: $1,041 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,878.39 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,153.67 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,039.02 | 2019-2025 | Fasenra, Andexxa, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,020.24 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $569.36 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $427.40 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $374.59 | 2019-2025 | Prolastin-C Liquid |
| Noctrix Health, INC. | $336.86 | 2025 | Nidra |
| Insmed, INC. | $277.70 | 2019-2025 | Arikayce |
| Pfizer INC. | $254.01 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $242.76 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $199.08 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.85 | 2019-2025 | |
| Lilly USA, LLC | $183.04 | 2025 | Zepbound |
| Genzyme Corporation | $171.12 | 2019-2025 | |
| Genentech USA, INC. | $162.79 | 2019-2020 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $158.53 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $138.04 | 2025 | Neffy |
| Inspire Medical Systems, INC. | $124.50 | 2023-2025 | Inspire |
| Electromed, INC. | $122.33 | 2022-2025 | Smartvest |
| United Therapeutics Corporation | $120.30 | 2021-2024 | Tyvaso |
| Philips North America LLC | $117.47 | 2019-2025 | Vest Therapy Und |
| Baxter Healthcare | $114.05 | 2022-2025 | Hillrom - Life 2000 Ventilation System |
| Merck Sharp & Dohme LLC | $113.69 | 2023-2025 | Winrevair, Recarbrio, Zerbaxa |
| Resmed Corp | $110.17 | 2020-2025 | |
| Paratek Pharmaceuticals, INC. | $110.12 | 2022-2025 | Nuzyra |
| Advanced Respiratory, INC | $104.25 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.23 | 2020-2025 | Glassia |
| Alexion Pharmaceuticals, INC. | $74.68 | 2022 | |
| Amgen INC. | $74.51 | 2022 | |
| Shionogi INC | $59.13 | 2021-2025 | Fetroja |
| Sunovion Pharmaceuticals INC. | $58.41 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $57.52 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $51.31 | 2024-2025 | Lumryz |
| Pulmonx Corporation | $50.32 | 2023 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Viatris Specialty LLC | $44.66 | 2025 | Yupelri |
| La Jolla Pharmaceutical Company | $40.53 | 2019-2025 | Giapreza |
| Harmony Biosciences LLC | $36.05 | 2022-2025 | |
| Axsome Therapeutics, INC. | $34.47 | 2025 | Sunosi |
| Tactile Systems Technology INC | $33.98 | 2025 | Nimbl, Flexitouch Plus |
| Verona Pharma, INC. | $31.69 | 2025 | Ohtuvayre |
| Melinta Therapeutics, LLC | $20.30 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.93 | 2024 | Acthar |
| Tetraphase Pharmaceuticals, INC. | $16.97 | 2019 | |
| Optinose US, INC. | $16.77 | 2024 | |
| Gilead Sciences, INC. | $14.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.